GMAB
Genmab A/SBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
GMAB vs peer average
68/100
GMAB vs. peer average (B vs. C)
Grade spread
B 1 · C 7 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
ASND is the first available peer comparator.
Ascendis is a smaller Nordic biopharma with an approved product and pipeline, making it a useful size-and-execution peer, though its therapeutic mix is less oncology-heavy than Genmab's.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GMAB
Genmab A/S
ASND
Ascendis A/S
Grade
B
F
Momentum
46
68
Value
65
48
Sentiment
64
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs ASND
GMAB / ASND
Grade Position
In line
GMAB vs. peer average (B vs. C)
68/100
Momentum
46
ASNDValue
65
GMABSentiment
64
GMABRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GMAB
ASND is the first peer returned for this comparison set.